Neurological Diseases– tag –

Strategic Review: Rare Disease, GI, Vaccines, and Innovation Takeda has transformed itself into a global biopharma leader through acquisitions such as Nycomed in 2011 (expanding GI/respiratory reach in Europe), Shire in 2018 (rare diseas...

Strategic Review: Diversifying Beyond Humira AbbVie has proactively diversified its portfolio beyond Humira, expanding into oncology, neuroscience, immunology, ophthalmology, and aesthetics. Its acquisition of Allergan, ADC platforms, an...